E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with idiopathic pulmonary fibrosis (IPF) |
pacientes con fibrosis pulmonar idiopática (FPI) |
|
E.1.1.1 | Medical condition in easily understood language |
serious scarring disease of the lung |
enfermedad grave de cicatrización del pulmón |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021240 |
E.1.2 | Term | Idiopathic pulmonary fibrosis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067761 |
E.1.2 | Term | Exacerbation of idiopathic pulmonary fibrosis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•Efficacy of TD139 by assessing the annual rate of decline in Forced Vital Capacity (FVC; expressed in mL over 52 weeks) |
Eficacia de TD139 evaluando la tasa anual de deterioro de la Capacidad Vital Forzada (CVF, expresada en ml a lo largo de 52 semanas) |
|
E.2.2 | Secondary objectives of the trial |
•Proportion of subjects with an absolute decline from baseline in FVC % pred of >10% at w52 •Time to first hospitalization (IPF related, including acute exacerbation of IPF) . •Time to death (all-causes, respiratory-related causes and/or caused by IPF) Additional secondary and exploratory efficacy variables with bearing on the efficacy of TD139 (e.g. QoL) are described in detail in the Main Criteria and Evaluation and Analyses ) |
• Proporción de pacientes con un deterioro absoluto en la semana 52 de >10 % respecto al inicio del porcentaje del valor predicho de CVF • Tiempo hasta la primera hospitalización (relacionada con la FPI incluidala exacerbación aguda de la FPI) • Tiempo hasta la muerte (por todas las causas, por causas respiratorias y/o provocadas por la FPI). • Las variables de eficacia secundarias y exploratorias adicionales con repercusión en la eficacia de TD139 (p. ej., la CdV) se describen detalladamente más adelante en los Principales criterios para evaluación y análisis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male and female subjects aged ≥ 40 years of age with a diagnosis of IPF established during the previous three years according to ATS/ERS/Fleischner criteria. A historical diagnostic HRCT scan assessed according to the ATS/ERS/Fleischner criteria must be available from within the 12 months prior to screening. Diagnostic HRCTs will be subject to central reading for confirmation. 2.Lung function parameters as follows: a.FVC > 45% of the predicted value at screening b.DLCO (corrected for Hb) of 30% to 79% of the predicted value at screening. 3.Any existing SoC treatment (e.g. pirfenidone or nintedanib in the SoC1 group but excluding prohibited medicines) must be deemed as stable in terms of dosing regimen, and tolerability by the PI/treating physician before randomization into the study. 4.Subjects must sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures |
1. Pacientes, varones y mujeres, de ≥ 40 años de edad con un diagnóstico de FPI confirmado durante los tres años anteriores de acuerdo con los criterios ATS/ERS/Fleischner. Debe hallarse disponible una exploración diagnóstica por TCAR histórica, evaluada de acuerdo con los criterios ATS/ERS/Fleischner, de los 12 meses anteriores a la selección. Las TCAR diagnósticas se someterán a una lectura central para su confirmación. 2. Parámetros de la función pulmonar con los siguientes valores: a. CVF >45 % del valor predicho en la selección b. DLCO (corregida para Hb) de entre el 30 % y el 79 % valor predicho en la selección. 3. Antes de la aleatorización en el estudio, el IP/médico responsable deberá considerar que el TE (p. ej., pirfenidona o nintedanib en el grupo de TE1, pero excluyendo los medicamentos prohibidos) ha sido estable en cuanto a la pauta posológica y la tolerabilidad. 4. Los pacientes deberán firmar y fechar un formulario de consentimiento informado escrito y cualquier autorización necesaria antes del inicio de los procedimientos del studio. |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following exclusion criteria are not to be enrolled in the study/randomized to treatment: 1.Currently has significant airways obstruction: FEV1/FVC ratio of < 0.7 at screening 2.Has clinical evidence of active infection, including, but not limited to, bronchitis, pneumonia, sinusitis, urinary tract infection, and cellulitis. 3.Has a history of malignancy within the last 2 years with the exception of basal cell carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or managed by observation. 4.Has any condition other than IPF that, in the opinion of the investigator, is likely to result in the death of the subject within the next 2 years. 5.Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial 6.Is likely to receive lung transplantation within the next 12 months 7.Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil, azathioprine, cyclophosphamide, methotrexate), vasodilator therapy for pulmonary hypertension (e.g., bosentan), and or investigational therapy for IPF or administration of such therapeutics within 4 weeks of initial screening (or 5 half-lives, whichever is longer). Also see excluded concomitant medicines (Section 7.3). A current dose of less than or equal to 15 mg/day of prednisone or its equivalent is acceptable if the dose is anticipated to remain stable during the study. 8.Has a history of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous six months, including, but not limited to, the following: a.Unstable angina pectoris or myocardial infarction, or percutaneous coronary intervention within the last 6 months b.Congestive heart failure requiring hospitalization c.Uncontrolled clinically significant arrhythmias. 9.If female, the subject is pregnant or lactating or intending to become pregnant before participating in this study during the study and within (5 half- lives PLUS 30 days) after last dose of the study drug; or intending to donate ova during such time period. 10.Woman considered to be of childbearing potential who do not use highly effective birth control methods during the study. |
No se podrá incluir en el estudio o asignar aleatoriamente tratamiento a los pacientes que cumplan cualquiera de los criterios de exclusión siguientes: 1. Tener actualmente una obstrucción de las vías respiratorias significativa: cociente VEF1/CVF de <0,7 en la selección 2. Presentar signos clínicos de infección activa, incluidas, entre otras, bronquitis, neumonía, sinusitis, infección del tracto urinario y celulitis. 3. Tener antecedentes de neoplasia maligna en los últimos 2 años, a excepción del carcinoma basocelular, la leucemia linfocítica crónica (en observación) y el cáncer de próstata que requiera antiandrógenos, tratamiento localizado (cirugía menor, radioterapia) y/o manejo por observación. 4. Tener alguna patología distinta de la FPI que, en opinión de investigador, podría provocar la muerte del paciente en los 2 años siguientes. 5. La presencia de cualquier otra enfermedad que podría interferir en los procedimientos de las pruebas o que, a juicio del investigador, podría interferir en la participación en el ensayo o poner en riesgo al paciente al participar en este ensayo 6. Tener posibilidades de recibir un trasplante de pulmón en los 12 meses siguientes. 7. Estar recibiendo actualmente una dosis alta de corticoesteroides, citotóxicos (p. ej., clorambucilo, azatioprina, ciclofosfamida o metotrexato), un tratamiento vasodilatador para la hipertensión pulmonar (p. ej., bosentan) y/o un tratamiento en investigación para la FPI, o la administración de dichos tratamientos en el plazo de 4 semanas (o, si es más prolongado, en el de 5 semividas) anterior a la selección inicial. Ver también los medicamentos concomitantes excluidos (Sección 7.3). Se acepta una dosis actual igual o inferior a 15 mg/día de prednisona o equivalente si se prevé que la dosis va a permanecer estable durante el estudio. 8. Tener antecedentes de enfermedad cardíaca o pulmonar inestable o degenerativa (distinta de la FPI) en los seis meses anteriores, incluidas, entre otras, las siguientes: a. Angina de pecho o infarto de miocardio inestable, o intervención coronaria percutánea en los últimos 6 meses b. Insuficiencia cardíaca congestiva que requiera hospitalización c. Arritmias clínicamente significativas no controladas. 9. Si se trata de una paciente, estar embarazada o en período de lactancia, o tener previsto quedarse embarazada antes de la participación en este estudio, durante el estudio y después (5 vidas medias MAS 30 días) de la última dosis del medicamento del estudio; o con la intención de donar óvulos durante ese período de tiempo. 10. Las mujeres a las que se considere potencialmente fértiles y que no utilicen métodos anticonceptivos altamente eficaces durante el studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Efficacy of TD139 by assessing the annual rate of decline in Forced Vital Capacity (FVC; expressed in mL over 52 weeks) |
Eficacia de TD139 evaluando la tasa anual de deterioro de la Capacidad Vital Forzada (CVF, expresada en ml a lo largo de 52 semanas) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Proportion of subjects with an absolute decline from baseline in FVC (% pred) of >10% at w52. •Time to first hospitalization (IPF related, including acute exacerbation of IPF). •Time to death (from all-causes, respiratory-related causes and/or caused by IPF) . |
• Proporción de pacientes con un deterioro absoluto en la semana 52 de >10 % respecto al inicio del porcentaje del valor predicho de CVF • Tiempo hasta la primera hospitalización (relacionada con la FPI incluidala exacerbación aguda de la FPI) • Tiempo hasta la muerte (por todas las causas, por causas respiratorias y/o provocadas por la FPI). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
•Week 52 •Time to first hospitalization •Time to death |
. 52 semanas .Tiempo hasta la primera hospitalización .Tiempo hasta la muerte |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 70 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
France |
Germany |
Ireland |
Israel |
Italy |
Poland |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
ultima visita del ultimo paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |